（文章来源：证券时报网） 中慧生物-B公布，由于黑色暴雨警告及2025年8月5日上午恶劣天气导致的极端情况，招股章程及正式通 告所载的全球发售预期时间表将据此推迟。公司谨此宣布，全球发售将采用经更新预期时间表，预期股 份将于2025年8月11日开始在联交所买卖。 ...

(责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 格隆汇8月5日｜中慧生物-B(2627.HK)在港交所发布公告称，由于黑色暴雨警告及2025年8月5日上午恶 劣天气导致的极端情况，招股章程及正式通告所载的全球发售预期时间表将据此推迟。全球发售将采用 经更新预期时间表，预期股份将于2025年8月11日(原定于8月8日)开始在联交所买卖。 ...

格隆汇8月5日丨中慧生物-B(02627.HK)公布，由于黑色暴雨警告及2025年8月5日上午恶劣天气导致的极 端情况，招股章程及正式通告所载的全球发售预期时间表将据此推迟。公司谨此宣布，全球发售将采用 经更新预期时间表，预期股份将于2025年8月11日开始在联交所买卖。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表聲明，並明確表示概不 會就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告僅作說明用途，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。 潛在投資者於決定是否投資所提呈發售的 H 股前，應閱覽江蘇中慧元通生物科技股份有限公司 （「本公司」）所刊發日期為 2025 年 7 月 31 日的招股章程（「招股章程」），以獲得下文所述有關全球 發售的詳細資料。有關發售股份的投資決定應以招股章程所載資料為唯一依據。 除本公告另有界定者外，本公告所用詞彙與招股章程所界定者具有相同涵義。 Ab&B Bio-Tech CO., LTD. JS 江 蘇 中 慧 元 通 生 物 科 技 股 份 有 限 公 司 （於中華人民共和國成立的股份有限公司） 由於天氣惡劣 延遲全球發售的預期時間表 茲提述本公司日期為2025年7月31日的招股章程及正式通知（ 「 通知」）。 除另有註明外，本公告所用詞彙與招股章程及正式通知所界定者俱有相同涵 ...

Group 1: IPO Market Overview - In the past week (July 28 - August 3, 2025), seven companies submitted IPO applications in the Hong Kong market, including YunTianLiFei (688343.SH), XinWangDa (300207.SZ), and DanNuo Pharmaceutical [3][4] - Two companies passed the Hong Kong Stock Exchange hearing: TianYue Advanced (688234.SH) and YinNuo Pharmaceutical [3][4] - One new company, ZhongHui Biological (02627.HK), initiated its IPO process, with no companies successfully listed during this period [3][4] Group 2: ZhongHui Biological - ZhongHui Biological officially launched its IPO on July 31, 2025, with a global offering of 33.4426 million shares, priced between HKD 12.90 and HKD 15.50 per share [3][17] - The expected listing date on the Hong Kong Stock Exchange is August 8, 2025 [3][17] - The company has secured cornerstone investors who agreed to subscribe for shares totaling approximately HKD 102 million [17][19] Group 3: YunTianLiFei - YunTianLiFei is a leading AI company in China, focusing on the research, design, and commercialization of AI inference chips [6] - The company ranks among the top three providers of AI inference chip-related products and services in China, based on revenue statistics for 2024 [7] - For the three months ending March 31, 2025, YunTianLiFei reported revenue of RMB 264 million, a year-on-year increase of 168.2%, but incurred a net loss of RMB 85.801 million, a decrease of 37.9% year-on-year [8] Group 4: XinWangDa - XinWangDa, a global leader in lithium battery technology, aims to provide integrated solutions for green and efficient energy [8] - The company has a diverse product matrix, including energy storage systems, consumer batteries, and power batteries [8] - For the three months ending March 31, 2025, XinWangDa recorded revenue of RMB 12.289 billion, a year-on-year increase of 12.0%, and a 21.3% increase in profit attributable to shareholders [9] Group 5: DanNuo Pharmaceutical - DanNuo Pharmaceutical is a biotechnology company focused on discovering, developing, and commercializing innovative drug products for bacterial infections and related diseases [10][11] - The company has established a pipeline of seven innovative assets, with no products currently approved for commercial sale [12][14] - For the three months ending March 31, 2025, DanNuo reported a net loss of RMB 38.011 million, an increase of 36.4% year-on-year [14] Group 6: TianYue Advanced - TianYue Advanced is a leading manufacturer of wide bandgap semiconductor materials, focusing on the research and industrialization of silicon carbide substrates [15] - The company ranks among the top three global manufacturers of silicon carbide substrates based on sales revenue for 2024 [15] - For the three months ending March 31, 2025, TianYue reported revenue of RMB 408 million, a year-on-year decrease of 4.2%, and a net profit of RMB 8.518 million, a decrease of 81.5% year-on-year [16] Group 7: YinNuo Pharmaceutical - YinNuo Pharmaceutical is a science-driven biopharmaceutical company focused on providing innovative and affordable high-quality drugs for metabolic diseases [16] - The company has developed a pipeline of candidate drugs targeting diabetes and other metabolic diseases, including a core product for treating obesity and related conditions [16] - For the five months ending May 31, 2025, YinNuo reported revenue of RMB 38.144 million, with a net loss of RMB 97.875 million, an increase of 58.1% year-on-year [16]

智通财经APP获悉，中慧生物-B(02627)正在招股中。截止8月4日，富途、辉立、华盛等券商合计为中慧生物-B借出931.1925亿港元，超 购逾1789倍。 | | | 新股孖展 (8月4日) | | | --- | --- | --- | --- | | 新股 | 券商 | 子展(亿港元) | 息率% | | 中慧生物- B(02627) | 富途 | 462.10 | 0.00 | | | 辉立 | 196.00 | 0.00 | | | रूह | 36.50 | 0.00 | | | 信诚 | 36.00 | 0.00 | | | 耀才 | 30.00 | 0.00 | | | 图立 | 6.463 | 0.00 | | | 时富 | 0.70- | 0.00 | | | 艾德 | 0.4634 | 0.00 | | | 其他总和 | 162.9661 | | | | 并计 | 931.1925 | | | | | 集资额：0.52亿元 | | | | | 认购:超购逾1789倍 | | ...

本文源自：智通财经网 智通财经获悉，中慧生物-B(02627)正在招股中。截止8月1日，富途、辉立、华盛等券商合计为中慧生 物-B借出321.9816亿港元，超购逾618倍。 ...

| 新股仔展 (8月1日) | | | | | --- | --- | --- | --- | | 券商 | | 息率(%) | 新股 | | 富途 | 129.60 | 0.00 | | | 辉立 | 75.00 | 0.00 | | | 华盛 | 34.20 | 0.00 | | | 10.00 | 0.00 | 耀才 | | | 信诚( | 6.00 | 0.00 | 中慧生物- | | 閣立 | 2.311 | 0.00 | B(02627) | | 0.4634 | 0.00 | 艾德 | | | 其他总和 | 64.4072 | | | | 并计 | 321.9816 | | | | 集资额: 0.52亿元 | | | | | 认购: 超购逾618倍 | | | | 智通财经APP获悉，中慧生物-B(02627)正在招股中。截止8月1日，富途、辉立、华盛等券商合计为中慧生物-B 借出321.9816亿港元，超购逾618倍。 ...

Major Events - JD Group-SW (09618) has decided to make a voluntary public acquisition offer to CECONOMY and establish a strategic investment partnership [1] - Zhonghui Biological-B (02627) plans to conduct an IPO from July 31 to August 5, aiming to globally offer 33.4426 million H-shares [1] - WuXi AppTec (02359) intends to place 73.8 million new H-shares at a discount of approximately 6.90%, raising about HKD 7.65 billion [1] - Weihai Bank (09677) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly HKD 3 billion [1] - HSBC Holdings (00005) plans to repurchase up to USD 3 billion of ordinary shares [1] - Joy City Property (00207) proposes a share buyback through an agreement arrangement, with resumption of trading on August 1 [1] Operating Performance - MGM China (02282) reported total revenue of HKD 16.661 billion for the first half, an increase of 2.73% year-on-year [1] - Standard Chartered Group (02888) released interim results with a profit attributable to shareholders of USD 3.065 billion, a year-on-year increase of 41% [1] - Autohome-S (02518) reported a net profit attributable to the parent of RMB 416 million in the second quarter, with online marketing and other business revenues increasing by 20.5% year-on-year [1] - Tongguan Gold (00340) issued a positive profit alert, expecting a mid-term profit attributable to shareholders of approximately HKD 330 million to HKD 360 million, a year-on-year increase of about 259% to 291% [1] - Qingdao Bank (03866) reported a net profit attributable to the parent of RMB 3.065 billion for the first half, a year-on-year increase of 16.05% [1] - Faraday (09638) announced interim results with a profit attributable to shareholders of EUR 4.3454 million, a year-on-year decrease of 0.92% [1] - Budweiser APAC (01876) released interim results with a profit attributable to shareholders of USD 409 million, a year-on-year decrease of 24.4% [1]

Core Viewpoint - The Hong Kong stock market has shown strength this month, with the Hang Seng Index rising by 2.91%, the Tech Index by 2.83%, and the State-Owned Enterprises Index by 2.36% [1] Company Overview - Zhonghui Biotech, established in 2015 and headquartered in Taizhou, Jiangsu, focuses on innovative vaccines and traditional vaccine development using new technologies [2][4] - The company has a commercialized product, Huierkangxin, which is the first and only approved subunit quadrivalent influenza vaccine in China [2] - Zhonghui Biotech's pipeline includes 11 other vaccines in development, targeting major diseases such as pneumonia and RSV [2] Financial Performance - For the fiscal year ending December 31, 2023, Zhonghui Biotech reported revenues of RMB 52.168 million, with a net loss of RMB 424.741 million [3] - The company’s revenue for Q1 2025 is projected at RMB 413,000, with a corresponding net loss of RMB 87.317 million [3] - As of the end of 2024, the company had cash and cash equivalents of approximately RMB 130 million, with net current liabilities of RMB 470 million [4] IPO Information - Zhonghui Biotech plans to issue 33.4426 million shares, with a price range of HKD 12.9 to 15.5, aiming to raise approximately HKD 518 million [8] - The IPO will account for 8.5% of the total shares, with one cornerstone investor committing to HKD 102 million [8] - The expected subscription rate for the IPO is projected to be around 2000 times, with an estimated 5% chance of winning a share [9] Market Competition - The influenza vaccine market in China is highly competitive, with 19 existing products and 16 in clinical development [6] - Major competitors have significantly reduced their vaccine prices, while Zhonghui Biotech's product is priced at HKD 319, which is substantially higher than the market average [6] - The company's valuation at the IPO price suggests a high price-to-sales ratio of 23.5 times, indicating a premium compared to peers [6] Investment Sentiment - Recent trends in the Hong Kong stock market have been favorable for biotech IPOs, with heightened investor interest following the successful debut of other biotech stocks [11] - Despite the company's financial challenges, the current market sentiment may support a positive reception for the IPO [11]